Viome Life Sciences announced a $25 million internal Series D and the appointment of its new chief operating officer, Kal Raman.
Khosla Ventures, Marc Benioff, Bold Capital WRG Ventures and others participated in the round.
Raman joins Viome as COO after previously holding the position of senior vice president of non-media business, marketing and retail technology at Amazon and chief digital...
Viome Life Sciences, maker of at-home tests for gut and immune system health, announced it has acquired digital health-and-wellness data company Naring Health, including its subsidiaries DiscernDX and Foodome.
Viome is split into two divisions, one selling consumer products like microbiome tests that provide diet recommendations and supplements, and the other focused on identifying biomarkers...
Allergy testing and treatment company Nectar Life Sciences announced the opening of the Nectar Allergy Center in New York, its first brick-and-mortar clinic, to expand its virtual care platform to a hybrid model.
Nectar, which launched earlier this year, offers at-home testing kits. Individuals can self-test for indoor or outdoor allergies and send their samples to Nectar for results.
Testers...
California-based diagnostics startup Simple HealthKit announced that it is partnering with Walmart to make its home diagnostic test kits for diabetes, sexual wellness and respiratory health available to customers via the retail chain's website.
Simple HeathKit's sexual health test kit can identify gonorrhea, chlamydia and trichomoniasis. Its respiratory test can detect influenza and respiratory...
Digital diagnostics company ixlayer announced it will produce CVS Health's branded at-home sample collection kits.
Ixlayer's kits can test for Lyme disease, Vitamin D levels, thyroid function and sexually transmitted infections. Users are also provided education and information about what the results mean.
Consumers can now purchase the CVS Health-branded tests online or pick up a test in-store...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home.
Developed by Cue Health, the Cue COVID-19 Test for Home and Over the Counter Use was first authorized for point-of-care use last June.
It uses a nasal swab sample collected from the lower nose to detect the presence of SARS-CoV-2 RNA, and...
Reperio Health, the maker of an app-connected home wellness assessment kit marketed to employers, has raised $6 million is seed funding. The round was co-led by Caduceus Capital Partners and Rogue Venture Partners, and saw participation from Liquid 2 Ventures and G Ventures.
WHAT IT DOES
To enable at-home screenings, the Portland, Oregon-based company ships a kit directly to employees or...
Everlywell, a digital consumer platform for ordering and viewing lab tests from home, has closed an oversubscribed $175 million Series D funding round, the Austin, Texas-based company announced this morning.
The raise brought in a slew of new investors hailing from BlackRock, the Chernin Group, Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures and Portfolia. It also saw...
Yesterday afternoon, the U.S. FDA issued an Emergency Use Authorization (EUA) to a COVID-19 molecular diagnostic test that provides individuals with a result within 30 minutes, in the comfort of their home.
As opposed to currently available at-home testing products, which have patients self-collect a nasal swab sample and ship it for processing in a lab, the Lucira COVID-19 All-in-One Test Kit...
Just two months after closing its Series B funding, Truepill, a digital pharmacy that focuses on APIs, telehealth practitioners and pharmacy fulfillment services, announced a new $75 million Series C funding round.
The funding, which will help kick off the company's at-home lab testing efforts, was led by Oak HC/FT with participation from Optum Ventures, TI Platform Management, Sound Ventures...
